Results 211 to 220 of about 161,796 (303)

Cellular basis of HFpEF: contributions of abnormal lipids. [PDF]

Front Cardiovasc Med
Chiang HH, Akyol O, Tsai MH, Hochman-Mendez C, Elgalad A, Woodside D, Chen CH, Bhatt DL.   +7 more
europepmc   +1 more source

Enhancing Meat Quality Through Dietary Fiber: Insights Into the Gut Microbiota‐Derived Short‐Chain Fatty Acids‐Muscle Axis

Animal Research and One Health, EarlyView.
Dietary fiber (DF) modulates meat quality through the gut‐muscle axis by reshaping gut microbiota, improving intestinal integrity, reducing inflammation, and regulating muscle metabolism. These mechanisms influence muscle fiber characteristics and post‐mortem biochemistry, thereby enhancing tenderness, juiciness, color, flavor, and nutritional value of
Zeshan Zulfiqar, Muhammad Arslan Asif, Layla Al‐Mitib, Nabeela Ashiq, Haojie Wang, Yalei Cui, Boshuai Liu, Shucheng Huang, Yinghua Shi   +8 more
wiley   +1 more source

Lipid dynamics and cardiovascular risk profiles on carbohydrate- or saturated fat-based diets: secondary analysis of the CARBFUNC trial. [PDF]

EBioMedicine
Loddervik C, Laupsa-Borge J, Sommersten CH, Amundsen K, Ulvik A, Johannessen KK, Halvorsen S, Larsen TH, Nygård OK, Dierkes J, Mellgren G, Dankel SN.   +11 more
europepmc   +1 more source

Pathophysiological Mechanisms of Emaciation Syndrome in Plectropomus leopardus: Insights From Histology and Transcriptomics

Animal Research and One Health, EarlyView.
Integrated phenotypic, histological, transcriptomic, and validation analyses reveal that emaciation syndrome in Plectropomus leopardus is associated with intestinal structural damage, hepatic metabolic remodeling, and muscle protein degradation, highlighting coordinated multi‐tissue alterations underlying disease progression.
Zhihao Zhang, Bo Wang, Mengya Wang, Haizhan Tang, Mingjian Liu, Da Zheng, Zhongyi Zhai, Jiahang Li, Jinyang Xie, Chaofan Jin, Jingjie Hu, Zhenmin Bao   +11 more
wiley   +1 more source

Unmet Cardiovascular Risk Beyond LDL-C: A Perspective on Managing Residual Cardiovascular Risk. [PDF]

Pharmaceuticals (Basel)
Kypreos KE, Gafencu AV, Andreopoulou O, Zvintzou E, Marinos K, Mparnia V, Alemi M, Daraban BS, Multescu MG, Ghinea M, Mirancea O.   +10 more
europepmc   +1 more source

Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Rheumatoid arthritis (RA) is a complex systemic disorder characterized primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease, such as that of the lung, with potentially devastating clinical consequences. The critical importance of comorbidities,
Aurelie Najm, Lyn D. Ferguson, Iain B. McInnes   +2 more
wiley   +1 more source

Non-HDL Cholesterol as a Practical Gatekeeper for Adolescent Dyslipidemia Screening: Implications for Nutrition and Public Health. [PDF]

Nutrients
Nakamura K, Okada T, Watanabe N, Sato H, Kagawa Y, Kawahara H, Sakamoto T, Yamasaki S, Tanabe J, Furuta M, Kawanami Y, Miki Y, Endo A.   +12 more
europepmc   +1 more source

T cells, the Next Big Target in Axial Spondyloarthritis?

Arthritis &Rheumatology, EarlyView.
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by complex immune dysregulation, with T cells playing a central role in its pathogenesis. In this review, we synthesize current knowledge on diverse T cell subsets in axSpA, their pathogenic mechanisms, and emerging therapeutic strategies targeting these cells. We highlight
Mansi K. Aparnathi, Nigil Haroon
wiley   +1 more source

Triglyceride-Rich Lipoproteins and ASCVD: Evidence for Causality and Challenges in Therapeutic Translation. [PDF]

Curr Atheroscler Rep
Björnson E, Adiels M.
europepmc   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source